Elicio Therapeutics Q2 net loss narrows as R&D expenses fall

Elicio Therapeutics

13/08/2026 21:09

Overview
US biotech firm's Q2 net loss narrowed yr/yr as R&D expenses declined
Company completed $15 mln financing in July, extending cash runway into Q1 2027
Phase 2 AMPLIFY-7P trial for ELI-002 7P in pancreatic cancer did not meet primary endpoint

Outlook
Elicio expects to initiate a Phase 1 combination trial in metastatic pancreatic cancer in Q4 2026
Company says current cash and equivalents expected to support operations into Q1 2027
Elicio continues to evaluate Phase 2 subgroups to refine Phase 3 development strategy for ELI-002 7P

Result Drivers
LOWER CLINICAL TRIAL COSTS - Co said decrease in R&D expense was mainly due to lower clinical trial costs as patients moved from active dosing to follow-up in Phase 2 ELI-002 7P study
COMPLETE RESPONSES OBSERVED - Co reported multiple complete responses following ELI-002 7P treatment and checkpoint inhibition in metastatic pancreatic cancer
SUBGROUP ANALYSIS CONTINUES - Co continues to evaluate pre-specified subgroups from Phase 2 AMPLIFY-7P trial to refine Phase 3 development strategy for ELI-002 7P

Company press release: ID:nGNX8KrK84

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$8.22 mln
 
Q2 Income from Operations
 
-$10.43 mln
 
Q2 Loss Per Basic Share
 
$0.43
 
Q2 Operating Expenses
 
$10.43 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Elicio Therapeutics Inc is $23.00, about 651.6% above its August 12 closing price of $3.06

Reuters Recommended Reads
Aug 13 - Artelo Biosciences Q2 net loss narrows as R&D expenses fall
Aug 11 - Cardiff Oncology Q2 operating expenses fall on lower R&D costs
Aug 11 - Oncology firm Immunome's Q2 net loss widens as R&D costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)